Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective, Randomised, Open-label, Blinded End-point Trial (APIDP2)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 178 participants.
Also called NCT06045858
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 178 participants
- Sponsor
- Registry
-
NCT06045858 -
2023-507544-37-00
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06045858. Randomized; single masking; primary purpose treatment. Start 2024-10-30 (anticipated); primary completion 2027-10-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective, Randomised, Open-label, Blinded End-point Trial (APIDP2)
- Acronym
- APIDP2
- Condition
- Atrial Fibrillation
- Condition
- Peritoneal Dialysis Complication
- Intervention (Drug)
- Anticoagulation Agents
- Lead sponsor
- University Hospital, Caen
Record details
- Record id
cardio:ct-nct06045858- Content hash
6db0eb2238728d53428b85ed7622732c857250b2c2f7a31993301bf7c90b79f6